BenzingaApr 10, 9:55 AM ET▲ Positive
Phase 2b trial results published in Cell Stem Cell showing improved physical condition in age-related frailty patients; granted patent protection through 2038; five FDA designations across programs.
Longeveron news
$2.72+3.42%
Close Sep 29, 2026 · split-adjustedArticles · 30 days0English, de-duplicated
Positive0
Neutral0
Negative0
About Longeveron
No recent articles focused on Longeveron.
Also mentions LGVN
Articles that tag LGVN but are mainly about other companies.
BenzingaMar 18, 10:00 AM ETNeutral
Mentioned as advancing stem cell therapy for age-related frailty with positive Phase 2b results, but no specific news or developments disclosed in this article.
BenzingaMar 3, 10:02 AM ET▲ Positive
Published Phase 2b clinical trial results in Cell Stem Cell demonstrating laromestrocel improved physical condition in age-related frailty patients with clinically meaningful dose-dependent improvements.
Articles and sentiment ratings from Massive / Polygon. Sentiment is the provider's model rating for this company, not Gainbot's view.
Sources: Massive / Polygon daily aggregates (split-adjusted) · SEC filings via Massive · FINRA settlements via Massive · Financial Modeling Prep. Figures are dated where shown; research is informational, not investment advice. Methodology